Hanmi Science Co., Ltd. (008930.KS)
- Previous Close
30,550.00 - Open
30,800.00 - Bid 31,000.00 x --
- Ask 31,050.00 x --
- Day's Range
30,700.00 - 31,100.00 - 52 Week Range
29,850.00 - 56,200.00 - Volume
36,647 - Avg. Volume
306,042 - Market Cap (intraday)
2.051T - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Jul 26, 2024 - Jul 30, 2024
- Forward Dividend & Yield 200.00 (0.65%)
- Ex-Dividend Date Dec 27, 2023
- 1y Target Est
--
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.
www.hanmiscience.co.krRelated News
Performance Overview: 008930.KS
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 008930.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 008930.KS
Valuation Measures
Market Cap
2.02T
Enterprise Value
2.20T
Trailing P/E
17.26
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.62
Price/Book (mrq)
2.50
Enterprise Value/Revenue
1.73
Enterprise Value/EBITDA
14.09
Financial Highlights
Profitability and Income Statement
Profit Margin
9.41%
Return on Assets (ttm)
2.93%
Return on Equity (ttm)
15.31%
Revenue (ttm)
1.28T
Net Income Avi to Common (ttm)
120.14B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
31.55B
Total Debt/Equity (mrq)
26.34%
Levered Free Cash Flow (ttm)
42.26B